Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-Controlled Studies (vol 36, pg 1130, 2014)

被引：0
|
作者：
Lehrke, M.
机构：
来源：
CLINICAL THERAPEUTICS | 2014年 / 36卷 / 11期
关键词：
D O I：
10.1016/j.clinthera.2014.10.017
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1705 / 1705
页数：1
相关论文
共 50 条
  • [21] Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials
    Watada, Hirotaka
    Yamauchi, Toshimasa
    Yamamoto, Fumiko
    Taniguchi, Atsushi
    Yarush, Larisa
    Heilmann, Clemens
    Yasui, Atsutaka
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (09) : 1193 - 1202
  • [22] Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: Pooled analysis of data from three placebo-controlled phase III trials
    Del Prato, Stefano
    Taskinen, Marja-Riitta
    Owens, David R.
    von Eynatten, Maximilian
    Emser, Angela
    Gong, Yan
    Chiavetta, Silvia
    Patel, Sanjay
    Woerle, Hans-Juergen
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2013, 27 (03) : 274 - 279
  • [23] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Samuel S. Engel
    Elizabeth Round
    Gregory T. Golm
    Keith D. Kaufman
    Barry J. Goldstein
    Diabetes Therapy, 2013, 4 : 119 - 145
  • [24] Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Engel, Samuel S.
    Round, Elizabeth
    Golm, Gregory T.
    Kaufman, Keith D.
    Goldstein, Barry J.
    DIABETES THERAPY, 2013, 4 (01) : 119 - 145
  • [25] Safety and tolerability of alogliptin in patients with type 2 diabetes: pooled analysis of 20 double-blind randomised controlled clinical studies
    Munsaka, M. S.
    Smith, N.
    Lee, D.
    Wilson, C.
    DIABETOLOGIA, 2016, 59 : S371 - S371
  • [26] Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials
    Inagaki, Nobuya
    Sheu, Wayne H. -H.
    Owens, David R.
    Crowe, Susanne
    Bhandari, Amit
    Gong, Yan
    Patel, Sanjay
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2016, 30 (08) : 1622 - 1630
  • [27] Efficacy and safety of linagliptin plus insulin in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
    Yang, Wenying
    Shen, Jie
    Ye, Binqi
    Qi, Sheng
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35
  • [28] Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies
    Samuel S. Engel
    Elizabeth Round
    Gregory T. Golm
    Keith D. Kaufman
    Barry J. Goldstein
    Diabetes Therapy, 2013, 4 : 487 - 487
  • [29] Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
    Zinman, Bernard
    Ahren, Bo
    Neubacher, Dietmar
    Patel, Sanjay
    Woerle, Hans-Juergen
    Johansen, Odd Erik
    CANADIAN JOURNAL OF DIABETES, 2016, 40 (01) : 50 - 57
  • [30] Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis
    Qiu, Rong
    Balis, Dainius
    Xie, John
    Davies, Michael J.
    Desai, Mehul
    Meininger, Gary
    CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (03) : 553 - 562
12345